Free Trial

Apellis Pharmaceuticals (APLS) Competitors

Apellis Pharmaceuticals logo
$19.58 +0.19 (+0.98%)
Closing price 04:00 PM Eastern
Extended Trading
$19.61 +0.03 (+0.17%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

APLS vs. BPMC, ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TLX, TGTX, and NUVL

Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Apellis Pharmaceuticals vs.

Blueprint Medicines (NASDAQ:BPMC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.

In the previous week, Blueprint Medicines had 43 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 51 mentions for Blueprint Medicines and 8 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.76 beat Blueprint Medicines' score of 0.23 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Blueprint Medicines
14 Very Positive mention(s)
10 Positive mention(s)
13 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
Apellis Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Blueprint Medicines has higher earnings, but lower revenue than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$562.12M14.70-$67.09M-$2.47-51.81
Apellis Pharmaceuticals$775.84M3.14-$528.63M-$1.79-10.83

Blueprint Medicines has a net margin of -13.19% compared to Apellis Pharmaceuticals' net margin of -34.97%. Blueprint Medicines' return on equity of -77.49% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Blueprint Medicines-13.19% -77.49% -20.84%
Apellis Pharmaceuticals -34.97%-103.11%-28.96%

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Blueprint Medicines has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Blueprint Medicines presently has a consensus price target of $129.35, indicating a potential upside of 1.08%. Apellis Pharmaceuticals has a consensus price target of $40.05, indicating a potential upside of 106.56%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines
0 Sell rating(s)
16 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32
Apellis Pharmaceuticals
0 Sell rating(s)
9 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.62

Blueprint Medicines received 202 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 66.29% of users gave Apellis Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Blueprint MedicinesOutperform Votes
554
66.99%
Underperform Votes
273
33.01%
Apellis PharmaceuticalsOutperform Votes
352
66.29%
Underperform Votes
179
33.71%

Summary

Blueprint Medicines and Apellis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.

Get Apellis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLS vs. The Competition

MetricApellis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.44B$6.70B$5.50B$8.63B
Dividend YieldN/A2.50%5.27%4.19%
P/E Ratio-9.558.6627.1620.15
Price / Sales3.14255.59413.26161.57
Price / CashN/A65.8538.2534.64
Price / Book11.826.626.964.72
Net Income-$528.63M$143.26M$3.23B$248.00M
7 Day Performance3.03%9.23%5.21%3.71%
1 Month Performance12.08%18.26%13.97%10.34%
1 Year Performance-53.50%8.62%32.33%15.16%

Apellis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLS
Apellis Pharmaceuticals
4.6334 of 5 stars
$19.58
+1.0%
$40.05
+104.6%
-52.0%$2.46B$775.84M-9.65770Analyst Revision
BPMC
Blueprint Medicines
0.9112 of 5 stars
$127.79
+26.1%
$125.69
-1.6%
+23.8%$8.25B$562.12M-118.32640High Trading Volume
ROIV
Roivant Sciences
2.3488 of 5 stars
$11.17
+1.6%
$17.50
+56.7%
+5.8%$7.97B$29.05M-74.46860
RVMD
Revolution Medicines
3.8814 of 5 stars
$40.65
+3.2%
$67.08
+65.0%
+0.6%$7.57B$742,000.00-11.32250
VRNA
Verona Pharma
1.7411 of 5 stars
$84.10
+3.6%
$82.13
-2.3%
+597.8%$6.82B$118.54M-43.8030
BBIO
BridgeBio Pharma
4.5361 of 5 stars
$35.46
+3.5%
$57.09
+61.0%
+44.3%$6.73B$127.42M-12.44400Analyst Upgrade
Gap Up
ELAN
Elanco Animal Health
0.9412 of 5 stars
$13.44
0.0%
$15.17
+12.9%
-23.4%$6.67B$4.43B33.599,800Positive News
GRFS
Grifols
3.1206 of 5 stars
$8.30
-0.1%
N/A+22.0%$5.71B$7.21B7.0926,300
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.80
-1.1%
$22.00
+31.0%
N/A$5.68B$783.21M0.00N/APositive News
TGTX
TG Therapeutics
3.1447 of 5 stars
$35.75
+1.8%
$40.80
+14.1%
+151.4%$5.68B$386.39M-357.46290Analyst Revision
NUVL
Nuvalent
2.4678 of 5 stars
$77.18
+3.4%
$115.50
+49.7%
-3.9%$5.54BN/A-22.2440Positive News

Related Companies and Tools


This page (NASDAQ:APLS) was last updated on 6/10/2025 by MarketBeat.com Staff
From Our Partners